Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany

Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in western countries. Therapy is indicated in symptomatic and advanced stages and has changed fundamentally since 2010 when rituximab, an anti-CD20 antibody, has been approved for treatment of CLL. Until then therapy had been b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kajüter, Hiltraud, Wellmann, Ina, Khil, Laura, Jöckel, Karl-Heinz, Zhang, Can, Fink, Anna-Maria, Hallek, Michael, Stang, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556420/
https://www.ncbi.nlm.nih.gov/pubmed/34716290
http://dx.doi.org/10.1038/s41408-021-00556-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556420/
https://www.ncbi.nlm.nih.gov/pubmed/34716290
http://dx.doi.org/10.1038/s41408-021-00556-7

Ejemplares similares